Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
mobile icon
Close
  • Menu
  • Setting

Signaling Pathways

Items 21-30 of 36

Page
per page
  1. XL019
    A3937 XL019
    Target: JAK
    Summary: JAK2 inhibitor,potent and selective
      insoluble in EtOH; insoluble in H2O; ≥11.125 mg/mL
  2. Compound 56
    A8197 Compound 56
     1 Citation
    Target: EGFR
    Summary: REGFR inhibitor
      insoluble in H2O; ≥16.95 mg/mL
  3. PD153035 hydrochloride
    A8199 PD153035 hydrochloride
     1 Citation
    Target: EGFR
    Summary: Potent EGFR inhibitor
      insoluble in EtOH; insoluble in H2O; ≥3.97 mg/mL
  4. Ruxolitinib (INCB018424)
    A3012 Ruxolitinib (INCB018424)
     4 Citation
    Target: JAK
    Summary: JAK inhibitor
      insoluble in H2O; ≥15.32 mg/mL
  5. CUDC-101
    A4092 CUDC-101
     1 Citation
    Target: Histone Deacetylases (HDACs)|EGFR|ErbB
    Summary: Multitargeted HDAC inhibitor
      ≥21.7 mg/mL
  6. Tofacitinib (CP-690550) Citrate
    A4135 Tofacitinib (CP-690550) Citrate
     2 Citation
    Target: JAK
    Summary: Potent JAK inhibitor
      ≥25.22 mg/mL
  7. TG101348 (SAR302503)
    A4136 TG101348 (SAR302503)
     2 Citation
    Target: FLT3|JAK|c-RET
    Summary: JAK-2 inhibitor,potent and selective
      ≥26.23 mg/mL
  8. AZD1480
    A4137 AZD1480
    Target: JAK
    Summary: JAK2 inhibitor,ATP-competitive and novel
      insoluble in H2O; ≥93.8 mg/mL
  9. AG-490
    A4139 AG-490
     3 Citation
    Target: EGFR|JAK
    Summary: JAK2/EGFR inhibitor
      insoluble in H2O; ≥14.7 mg/mL
  10. WP1066
    A4140 WP1066
    Target: STAT|JAK
    Summary: JAK2/STAT3 inhibitor,cell-permeable
      insoluble in H2O; ≥17.8 mg/mL

Items 21-30 of 36

Page
per page